Leading a transformational approach to cell and gene therapies for diseases of the skin and connective tissue


Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The Company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell’s pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma. For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.

Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa
Thursday, October 3, 2019 at 2:00 PM PDT

Recent Happenings

Our News and Events

Sep 12, 2019
- Total consideration of $ 63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle Creek Pharmaceuticals as a leader in dermatology - EXTON, Pa. , Sept.
    Press Release

Thursday, October 3, 2019 at 2:00 PM PDT

View Event
Carlsbad, CA